Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.70 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.70 |
| ▸ | WNT1 | P04628 | 9/20 | 0.70 |
| ▸ | ABL1 | P00519 | 7/20 | 0.58 |
| ▸ | CLK2 | P49760 | 1/20 | 0.57 |
| ▸ | CLK3 | P49761 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | TYK2 | P29597 | 1/20 | 0.56 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19544479 | 1.00 | GSK3B (0.70) | GSK3BDYRK1AWNT1ABL1CLK2 | |
| SCHEMBL19515815 | 0.92 | GSK3B (0.73) | GSK3BDYRK1AWNT1ABL1JAK2 | |
| SCHEMBL25623359 | 0.89 | GSK3B (0.69) | GSK3BDYRK1AWNT1ABL1JAK2 | |
| SCHEMBL19516204 | 0.87 | GSK3B (0.70) | GSK3BDYRK1AWNT1ABL1CLK2 | |
| SCHEMBL23741077 | 0.87 | GSK3B (0.71) | GSK3BDYRK1AWNT1ABL1JAK2 | |
| SCHEMBL19515615 | 0.87 | GSK3B (0.71) | GSK3BDYRK1AWNT1ABL1JAK2 | |
| SCHEMBL30005237 | 0.87 | GSK3B (0.71) | GSK3BDYRK1AWNT1ABL1JAK2 | |
| SCHEMBL19515618 | 0.87 | GSK3B (0.71) | GSK3BDYRK1AWNT1ABL1JAK2 | |
| SCHEMBL19515737 | 0.85 | GSK3B (0.67) | GSK3BDYRK1AWNT1ABL1CLK2 | |
| SCHEMBL19515832 | 0.85 | GSK3B (0.65) | GSK3BDYRK1AWNT1ABL1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673881-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3943086-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | BioSplice Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-11174244-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3448838-B1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20200339536-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2020-10-29 | — | — | US | disclosed |
| US-10604514-B2 | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-03-31 | — | — | US | disclosed |
| US-10556885-B2 | Isoquinolin-3-YL carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-02-11 | — | — | US | disclosed |
| US-10508099-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2019-12-17 | — | — | US | disclosed |
| US-10287267-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190119263-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | MED-PATHWAYS II LIMITED (VG) | 2019-04-25 | — | — | US | disclosed |
| US-20170313681-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2017-11-02 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | GSK3B 685/4885DYRK1A 1064/4885WNT1 1140/4885 |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | GSK3B 685/4885DYRK1A 1064/4885WNT1 1140/4885 |
| US-10604514-B2 | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK2 | GSK3B 9/4885DYRK1A 1/4885WNT1 7/4885 |
| US-20190119263-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK3, DYRK2 | GSK3B 9/4885DYRK1A 1/4885WNT1 7/4885 |
| US-10556885-B2 | Isoquinolin-3-YL carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK1B | GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885 |
| US-20170313681-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK3, DYRK1B | GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885 |
| US-11673881-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK1B | GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885 |
| US-20200339536-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK3, DYRK1B | GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885 |
| US-10508099-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK1B | GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885 |
| US-10287267-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK1B | GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885 |
| US-11174244-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK1B | GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.